All Posts: immunotherapy
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
For the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining it with a drug that makes cancer cells more responsive to immunotherapy. The research is now in a phase 2 clinical trial being tested in human patients.
Category: Lombardi Stories
-
Understanding Immunotherapy Resistance Leads to New Therapeutic Strategies — and Hope
Samir Khleif, MD, an immunologist and professor of oncology at Georgetown Lombardi, is working to understand why some cancers become resistant to immunotherapy, and how that resistance can be overcome.
Category: Lombardi Stories
-
Atkins Inducted as Academy of Immuno-Oncology Fellow
The Society for Immunotherapy of Cancer (SITC) has inducted Georgetown Lombardi Deputy Director Michael B. Atkins, MD, as a Fellow of the Academy of Immuno-Oncology (FAIO). The 2023 class was inducted November 3 at the SITC’s 38th Annual Meeting in San Diego.
Category: Lombardi Stories
-
New Study Finds Personalized mRNA Vaccine Given with Immunotherapy Reduces Recurrence in High-Risk Melanoma Patients
A new study conducted by an international team of researchers, including clinical investigators at Georgetown University’s Lombardi Comprehensive Cancer Center, demonstrates that a personalized cancer mRNA vaccine combined with immunotherapy reduces recurrence and improves survival for people with advanced melanoma.
Category: Lombardi Stories
-
Key Studies Conducted at Georgetown Lombardi Lead to Better Treatment for People With Melanoma
(March 1, 2023) — Results from a pair of clinical trials published in recent months have changed the treatment landscape for people with advanced melanoma, offering a clearer path for improved survival. The studies, conducted at Georgetown University’s Lombardi Comprehensive Cancer Center and other cancer centers around the country, explored the best treatment options and […]
Category: Lombardi Stories
-
The Society for Immunotherapy of Cancer (SITC) Publishes a Checklist to Maximize the Benefit to Patients for Clinical Trials in Immuno-oncology
MILWAUKEE (October 6, 2022)— No uniform method has been established to predict the probability of success for individual clinical trials. To help identify clinical trials with a high likelihood of offering benefit to patients, the Society for Immunotherapy of Cancer (SITC) brought together a team of experts in immuno-oncology to create a conceptual framework for […]
Category: News Release
-
Advanced Melanoma Survival Improves Significantly When Immunotherapy is Given Before Targeted Therapy
The findings, coupled with results from another recent clinical trial, mark significant advances in the treatment of melanoma. WASHINGTON (September 27, 2022) — A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received […]
Category: News Release
-
Trial Stopped Early: Giving Immunotherapy Before Targeted Rx Improves Survival in Advanced Melanoma
WASHINGTON (November 15, 2021) — More people with advanced melanoma survive for two years or more when they receive a combination of two immunotherapy drugs given before a combination of two targeted therapies, if needed, compared to people who start treatment with targeted therapies. The finding comes from a clinical trial that was stopped early […]
Category: News Release
-
Experimental Drug Boosts Immunotherapy Effectiveness in Pancreatic Cancer in Mice
WASHINGTON (November 4, 2021) — An experimental drug enhanced the benefit of an immunotherapy to fight pancreatic cancer in mice by increasing the number of immune cells in the immediate vicinity of the tumor, leading to a reduction in tumor growth, and in some mice, eliminating their cancer. The findings, from researchers at Georgetown Lombardi […]
Category: News Release
-
Mechanism for How Pancreatic Cancer Evades Immunotherapy Elucidated
Discovery could lead to new or improved therapeutic options. WASHINGTON (January 28, 2021) — Pancreatic cancer, one of the most lethal of all cancers, is capable of evading attacks by immune cells by changing its microenvironment so that the immune cells suppress, rather than support, an attack on the tumor, according to a study led […]
Category: News Release